IPI-549 clinical trials
Also written IPI-549 and Eganelisib.
How each study uses IPI-549 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IPI-549 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Infinity Pharmaceuticals, Inc. (2) · Assuntina G. Sacco, MD (1) · Arcus Biosciences, Inc. (1) · Stelexis BioSciences (1) · Jacqueline Garcia, MD (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses IPI-549 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDSRecruitingPhase 1Stelexis BioSciencesNCT06533761Written as Eganelisib
- Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaRecruitingPhase 1Jacqueline Garcia, MDNCT07439211Written as Eganelisib
- IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaCompletedPhase 2Assuntina G. Sacco, MDNCT03795610Written as IPI-549
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT03719326Written as IPI-549
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)CompletedPhase 2Infinity Pharmaceuticals, Inc.NCT03980041Written as IPI-549 (eganelisib)
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownPhase 1Infinity Pharmaceuticals, Inc.NCT02637531Written as IPI-549 (eganelisib)
Given beside what is tested · 1 — IPI-549 is usual care or a partner of the new treatment
Codes
What other systems call IPI-549 · ClinicalTrials.gg INT001422
- MeSH (NLM) C000710654IPI-549One source NLM
- UNII (FDA) FOF5155FMZEGANELISIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710654 | IPI-549 | One source NLM |
| UNII (FDA) | FOF5155FMZ | EGANELISIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.